Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hematopoietic Stem Cell Transplantation | 101 | 2025 | 5709 | 9.240 |
Why?
|
Graft vs Host Disease | 62 | 2025 | 3042 | 8.220 |
Why?
|
Transplantation Conditioning | 31 | 2024 | 1598 | 2.790 |
Why?
|
Transplantation, Homologous | 29 | 2025 | 4834 | 1.710 |
Why?
|
Leukemia, Myeloid, Acute | 17 | 2023 | 3623 | 1.350 |
Why?
|
Bacteremia | 4 | 2020 | 985 | 1.350 |
Why?
|
Cord Blood Stem Cell Transplantation | 5 | 2021 | 305 | 1.300 |
Why?
|
Transplantation, Autologous | 10 | 2023 | 2126 | 1.290 |
Why?
|
Nitriles | 5 | 2025 | 984 | 1.220 |
Why?
|
Myelodysplastic Syndromes | 7 | 2022 | 1400 | 1.180 |
Why?
|
Hematologic Neoplasms | 9 | 2024 | 1905 | 1.010 |
Why?
|
Primary Myelofibrosis | 5 | 2024 | 209 | 0.910 |
Why?
|
Bronchiolitis Obliterans | 1 | 2025 | 220 | 0.850 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 4 | 2020 | 687 | 0.800 |
Why?
|
Pyrazoles | 5 | 2025 | 2024 | 0.780 |
Why?
|
Stem Cell Transplantation | 5 | 2023 | 1602 | 0.760 |
Why?
|
Vitamin A | 1 | 2024 | 611 | 0.730 |
Why?
|
Bone Marrow | 8 | 2024 | 2929 | 0.710 |
Why?
|
Heart Murmurs | 1 | 2020 | 92 | 0.680 |
Why?
|
Leukemia, Myeloid, Chronic-Phase | 2 | 2020 | 37 | 0.670 |
Why?
|
Sarcoma, Myeloid | 1 | 2020 | 52 | 0.660 |
Why?
|
Pyrimidines | 4 | 2025 | 3050 | 0.660 |
Why?
|
Erythroid Cells | 1 | 2021 | 238 | 0.660 |
Why?
|
Tacrolimus | 1 | 2022 | 750 | 0.630 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 3 | 2021 | 263 | 0.590 |
Why?
|
Central Nervous System Neoplasms | 4 | 2022 | 928 | 0.590 |
Why?
|
Humans | 135 | 2025 | 768451 | 0.540 |
Why?
|
Retroperitoneal Neoplasms | 1 | 2020 | 335 | 0.530 |
Why?
|
Heart Neoplasms | 1 | 2020 | 374 | 0.520 |
Why?
|
Philadelphia Chromosome | 1 | 2016 | 119 | 0.510 |
Why?
|
Bone Marrow Transplantation | 8 | 2024 | 2702 | 0.510 |
Why?
|
Lymphoma | 4 | 2022 | 1907 | 0.500 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2019 | 1557 | 0.500 |
Why?
|
Acute Disease | 10 | 2024 | 7246 | 0.490 |
Why?
|
Vision Disorders | 1 | 2022 | 1092 | 0.480 |
Why?
|
Immunotherapy, Adoptive | 6 | 2024 | 1505 | 0.450 |
Why?
|
Anemia, Refractory, with Excess of Blasts | 1 | 2013 | 17 | 0.440 |
Why?
|
Protein Kinase Inhibitors | 4 | 2021 | 5709 | 0.440 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 5 | 2023 | 11843 | 0.430 |
Why?
|
Lymphoma, Non-Hodgkin | 2 | 2018 | 1376 | 0.430 |
Why?
|
Adult | 54 | 2025 | 223542 | 0.420 |
Why?
|
Sarcopenia | 1 | 2018 | 376 | 0.410 |
Why?
|
Feces | 1 | 2019 | 1515 | 0.410 |
Why?
|
Iron-Dextran Complex | 1 | 2012 | 14 | 0.410 |
Why?
|
Respiratory Insufficiency | 1 | 2021 | 1244 | 0.410 |
Why?
|
Cyclophosphamide | 6 | 2023 | 2224 | 0.400 |
Why?
|
Steroids | 4 | 2023 | 937 | 0.400 |
Why?
|
Microscopic Polyangiitis | 1 | 2012 | 46 | 0.390 |
Why?
|
Histiocytic Necrotizing Lymphadenitis | 1 | 2012 | 27 | 0.390 |
Why?
|
Clostridium Infections | 1 | 2018 | 559 | 0.390 |
Why?
|
Recurrence | 12 | 2024 | 8510 | 0.370 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 1 | 2016 | 495 | 0.370 |
Why?
|
Busulfan | 4 | 2023 | 259 | 0.360 |
Why?
|
Middle Aged | 49 | 2025 | 223418 | 0.360 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 4 | 2022 | 1427 | 0.360 |
Why?
|
Immunoconjugates | 1 | 2018 | 968 | 0.350 |
Why?
|
Acetamides | 2 | 2022 | 260 | 0.350 |
Why?
|
Escherichia coli | 2 | 2019 | 4220 | 0.350 |
Why?
|
Aged | 37 | 2025 | 171520 | 0.350 |
Why?
|
Central Nervous System | 1 | 2017 | 1348 | 0.340 |
Why?
|
Hematinics | 1 | 2012 | 282 | 0.330 |
Why?
|
Male | 51 | 2025 | 364781 | 0.310 |
Why?
|
Algorithms | 5 | 2024 | 14158 | 0.310 |
Why?
|
Body Composition | 1 | 2018 | 2455 | 0.310 |
Why?
|
Receptors, Antigen, T-Cell | 3 | 2023 | 2568 | 0.300 |
Why?
|
Monitoring, Physiologic | 1 | 2015 | 1795 | 0.300 |
Why?
|
Anemia, Iron-Deficiency | 1 | 2012 | 373 | 0.290 |
Why?
|
Leukemia | 1 | 2016 | 1527 | 0.290 |
Why?
|
Thiotepa | 2 | 2017 | 66 | 0.290 |
Why?
|
Hematologic Diseases | 2 | 2023 | 499 | 0.290 |
Why?
|
Sarcoidosis | 1 | 2013 | 539 | 0.290 |
Why?
|
Fatal Outcome | 3 | 2019 | 1840 | 0.290 |
Why?
|
Retrospective Studies | 28 | 2024 | 81834 | 0.280 |
Why?
|
Exanthema | 1 | 2012 | 504 | 0.280 |
Why?
|
Treatment Outcome | 16 | 2025 | 65409 | 0.280 |
Why?
|
Leukemia, Plasma Cell | 2 | 2018 | 46 | 0.280 |
Why?
|
Female | 50 | 2025 | 396943 | 0.280 |
Why?
|
Remission Induction | 5 | 2022 | 2408 | 0.270 |
Why?
|
Meningeal Neoplasms | 1 | 2016 | 1251 | 0.270 |
Why?
|
Young Adult | 21 | 2024 | 60045 | 0.260 |
Why?
|
Melphalan | 3 | 2023 | 420 | 0.240 |
Why?
|
Receptor, Macrophage Colony-Stimulating Factor | 1 | 2024 | 94 | 0.230 |
Why?
|
Neoplasms, Second Primary | 3 | 2018 | 1062 | 0.230 |
Why?
|
Gastric Bypass | 1 | 2012 | 829 | 0.220 |
Why?
|
United States Food and Drug Administration | 2 | 2022 | 1669 | 0.220 |
Why?
|
Multiple Myeloma | 2 | 2024 | 5192 | 0.210 |
Why?
|
Eye Diseases | 2 | 2018 | 657 | 0.210 |
Why?
|
Antineoplastic Agents | 2 | 2016 | 13708 | 0.210 |
Why?
|
Anemia, Aplastic | 1 | 2024 | 231 | 0.200 |
Why?
|
Vidarabine | 2 | 2023 | 337 | 0.200 |
Why?
|
B-Lymphocytes | 1 | 2015 | 4781 | 0.200 |
Why?
|
Quality of Life | 13 | 2024 | 13497 | 0.200 |
Why?
|
Leukemia, Myelomonocytic, Chronic | 1 | 2023 | 93 | 0.200 |
Why?
|
Lymphoma, T-Cell, Peripheral | 1 | 2023 | 126 | 0.190 |
Why?
|
Tissue Donors | 4 | 2024 | 2377 | 0.190 |
Why?
|
Pilot Projects | 4 | 2024 | 8730 | 0.190 |
Why?
|
United States | 13 | 2024 | 73121 | 0.180 |
Why?
|
Mycophenolic Acid | 2 | 2020 | 350 | 0.180 |
Why?
|
Sexual Dysfunction, Physiological | 1 | 2024 | 363 | 0.180 |
Why?
|
Chimerism | 1 | 2021 | 156 | 0.180 |
Why?
|
Cardiovascular Diseases | 2 | 2016 | 15638 | 0.180 |
Why?
|
Combined Modality Therapy | 3 | 2017 | 8559 | 0.170 |
Why?
|
Interleukin 1 Receptor Antagonist Protein | 1 | 2022 | 299 | 0.170 |
Why?
|
Intestinal Mucosa | 2 | 2023 | 3048 | 0.170 |
Why?
|
Cytochrome P-450 Enzyme System | 1 | 2022 | 423 | 0.170 |
Why?
|
Blast Crisis | 2 | 2020 | 102 | 0.160 |
Why?
|
Multicenter Studies as Topic | 2 | 2024 | 1727 | 0.160 |
Why?
|
Myeloablative Agonists | 1 | 2019 | 210 | 0.160 |
Why?
|
Neoplasm Recurrence, Local | 7 | 2023 | 9425 | 0.160 |
Why?
|
Whole-Body Irradiation | 1 | 2019 | 434 | 0.160 |
Why?
|
Long QT Syndrome | 1 | 2023 | 472 | 0.150 |
Why?
|
Hepatic Encephalopathy | 1 | 2019 | 144 | 0.150 |
Why?
|
Chronic Disease | 6 | 2024 | 9382 | 0.150 |
Why?
|
Ciprofloxacin | 1 | 2020 | 313 | 0.150 |
Why?
|
Prospective Studies | 7 | 2025 | 54914 | 0.150 |
Why?
|
Premedication | 1 | 2018 | 246 | 0.150 |
Why?
|
Disease-Free Survival | 5 | 2023 | 6856 | 0.150 |
Why?
|
Neurotoxicity Syndromes | 1 | 2022 | 303 | 0.150 |
Why?
|
Immunity, Cellular | 1 | 2023 | 1561 | 0.150 |
Why?
|
Survival Analysis | 4 | 2018 | 10125 | 0.140 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2021 | 794 | 0.140 |
Why?
|
Antifungal Agents | 1 | 2022 | 761 | 0.140 |
Why?
|
beta-Lactamases | 1 | 2019 | 307 | 0.140 |
Why?
|
Thrombopoietin | 1 | 2019 | 226 | 0.140 |
Why?
|
Incidence | 6 | 2023 | 21552 | 0.140 |
Why?
|
Kaplan-Meier Estimate | 2 | 2017 | 6537 | 0.130 |
Why?
|
Myeloproliferative Disorders | 1 | 2022 | 614 | 0.130 |
Why?
|
Adolescent | 17 | 2024 | 89168 | 0.130 |
Why?
|
Empathy | 1 | 2021 | 476 | 0.130 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2021 | 1644 | 0.130 |
Why?
|
Mucositis | 1 | 2017 | 108 | 0.130 |
Why?
|
Gastrointestinal Tract | 2 | 2020 | 840 | 0.130 |
Why?
|
Survivors | 3 | 2024 | 2381 | 0.130 |
Why?
|
Hospitals, Special | 1 | 2015 | 90 | 0.120 |
Why?
|
Testicular Neoplasms | 1 | 2021 | 806 | 0.120 |
Why?
|
Hypogonadism | 1 | 2021 | 805 | 0.120 |
Why?
|
Antigens, CD34 | 1 | 2017 | 656 | 0.120 |
Why?
|
Cytarabine | 1 | 2017 | 697 | 0.120 |
Why?
|
Antibiotic Prophylaxis | 1 | 2020 | 640 | 0.120 |
Why?
|
Infertility | 1 | 2021 | 654 | 0.120 |
Why?
|
Interferon Type I | 1 | 2018 | 566 | 0.120 |
Why?
|
Child | 10 | 2024 | 80863 | 0.120 |
Why?
|
T-Lymphocytes | 5 | 2023 | 10273 | 0.120 |
Why?
|
Dacarbazine | 1 | 2017 | 560 | 0.110 |
Why?
|
Infusions, Intravenous | 2 | 2024 | 2228 | 0.110 |
Why?
|
Adrenal Cortex Hormones | 4 | 2024 | 1891 | 0.110 |
Why?
|
Iritis | 1 | 2013 | 15 | 0.110 |
Why?
|
Long-Term Care | 1 | 2018 | 633 | 0.110 |
Why?
|
Secondary Prevention | 2 | 2018 | 1479 | 0.110 |
Why?
|
Methotrexate | 2 | 2017 | 1722 | 0.110 |
Why?
|
Biological Products | 1 | 2022 | 937 | 0.110 |
Why?
|
Sarcoidosis, Pulmonary | 1 | 2013 | 45 | 0.110 |
Why?
|
Practice Guidelines as Topic | 3 | 2024 | 7451 | 0.110 |
Why?
|
Bone Marrow Examination | 1 | 2013 | 155 | 0.110 |
Why?
|
Clinical Trials as Topic | 2 | 2021 | 8051 | 0.100 |
Why?
|
Fetal Blood | 1 | 2019 | 1353 | 0.100 |
Why?
|
Drug Resistance, Bacterial | 1 | 2019 | 1064 | 0.100 |
Why?
|
Azacitidine | 1 | 2013 | 336 | 0.090 |
Why?
|
Affect | 1 | 2019 | 1498 | 0.090 |
Why?
|
Risk Factors | 12 | 2024 | 74915 | 0.090 |
Why?
|
Consensus | 1 | 2021 | 3207 | 0.090 |
Why?
|
Acute Kidney Injury | 1 | 2023 | 1943 | 0.090 |
Why?
|
Granuloma | 1 | 2013 | 331 | 0.090 |
Why?
|
Social Support | 1 | 2021 | 2195 | 0.090 |
Why?
|
Prognosis | 8 | 2024 | 30028 | 0.090 |
Why?
|
Indoles | 1 | 2018 | 1834 | 0.090 |
Why?
|
Societies, Medical | 2 | 2019 | 3955 | 0.090 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2024 | 10784 | 0.090 |
Why?
|
Antiviral Agents | 1 | 2022 | 3063 | 0.090 |
Why?
|
Body Mass Index | 2 | 2018 | 13030 | 0.090 |
Why?
|
Hodgkin Disease | 1 | 2017 | 1386 | 0.080 |
Why?
|
Postoperative Care | 1 | 2016 | 1481 | 0.080 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2013 | 647 | 0.080 |
Why?
|
Ferritins | 1 | 2012 | 601 | 0.080 |
Why?
|
Sepsis | 1 | 2023 | 2602 | 0.080 |
Why?
|
Bacterial Infections | 1 | 2017 | 1397 | 0.080 |
Why?
|
Antigens, CD19 | 2 | 2022 | 437 | 0.080 |
Why?
|
Breast Neoplasms | 1 | 2015 | 21156 | 0.080 |
Why?
|
Anxiety | 2 | 2020 | 4655 | 0.070 |
Why?
|
Mass Screening | 3 | 2024 | 5455 | 0.070 |
Why?
|
Caregivers | 1 | 2020 | 2302 | 0.070 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2024 | 10358 | 0.070 |
Why?
|
Sex Factors | 2 | 2018 | 10647 | 0.070 |
Why?
|
Age Factors | 3 | 2018 | 18478 | 0.070 |
Why?
|
Kidney Failure, Chronic | 1 | 2019 | 2489 | 0.070 |
Why?
|
Isocitrate Dehydrogenase | 2 | 2023 | 954 | 0.060 |
Why?
|
Guideline Adherence | 1 | 2015 | 2239 | 0.060 |
Why?
|
Administration, Oral | 1 | 2013 | 4041 | 0.060 |
Why?
|
Disease Management | 1 | 2015 | 2533 | 0.060 |
Why?
|
Bone Marrow Cells | 1 | 2012 | 2415 | 0.060 |
Why?
|
Gene Deletion | 1 | 2012 | 2674 | 0.060 |
Why?
|
Immunosuppressive Agents | 3 | 2024 | 4213 | 0.060 |
Why?
|
Kidney Transplantation | 1 | 2019 | 4285 | 0.060 |
Why?
|
Stress, Psychological | 1 | 2019 | 4538 | 0.050 |
Why?
|
Molecular Targeted Therapy | 1 | 2015 | 2834 | 0.050 |
Why?
|
Delivery of Health Care | 2 | 2018 | 5367 | 0.050 |
Why?
|
Acetonitriles | 1 | 2023 | 55 | 0.050 |
Why?
|
Probability | 2 | 2019 | 2483 | 0.050 |
Why?
|
Antilymphocyte Serum | 1 | 2024 | 491 | 0.050 |
Why?
|
Depression | 2 | 2020 | 8235 | 0.050 |
Why?
|
Follow-Up Studies | 3 | 2019 | 39430 | 0.050 |
Why?
|
Bilirubin | 1 | 2023 | 439 | 0.050 |
Why?
|
Time Factors | 4 | 2018 | 40271 | 0.050 |
Why?
|
Elafin | 1 | 2021 | 31 | 0.050 |
Why?
|
Anti-Bacterial Agents | 1 | 2020 | 7471 | 0.050 |
Why?
|
Renal Replacement Therapy | 1 | 2023 | 283 | 0.050 |
Why?
|
Receptors, Tumor Necrosis Factor, Type I | 1 | 2022 | 257 | 0.050 |
Why?
|
Biopsy | 1 | 2013 | 6816 | 0.050 |
Why?
|
Neoplasm Staging | 1 | 2016 | 11249 | 0.050 |
Why?
|
Obesity, Morbid | 1 | 2012 | 1309 | 0.050 |
Why?
|
Adaptation, Psychological | 2 | 2024 | 2665 | 0.050 |
Why?
|
Histiocytes | 1 | 2021 | 98 | 0.050 |
Why?
|
Ohio | 1 | 2021 | 328 | 0.040 |
Why?
|
rho-Associated Kinases | 1 | 2021 | 286 | 0.040 |
Why?
|
Risk Assessment | 4 | 2024 | 24311 | 0.040 |
Why?
|
Medicare | 1 | 2018 | 6881 | 0.040 |
Why?
|
Bacterial Translocation | 1 | 2018 | 74 | 0.040 |
Why?
|
Massachusetts | 2 | 2021 | 8908 | 0.040 |
Why?
|
Therapeutics | 1 | 2018 | 113 | 0.040 |
Why?
|
Tissue and Organ Harvesting | 1 | 2020 | 374 | 0.040 |
Why?
|
Cross-Sectional Studies | 3 | 2024 | 26351 | 0.040 |
Why?
|
Spleen | 1 | 2023 | 2298 | 0.030 |
Why?
|
Fatigue | 1 | 2024 | 1556 | 0.030 |
Why?
|
Diagnosis, Differential | 1 | 2012 | 13026 | 0.030 |
Why?
|
Antigens, Neoplasm | 1 | 2024 | 2003 | 0.030 |
Why?
|
Neoplasm, Residual | 1 | 2021 | 1014 | 0.030 |
Why?
|
Disease Progression | 2 | 2023 | 13655 | 0.030 |
Why?
|
Drug Resistance | 1 | 2021 | 1599 | 0.030 |
Why?
|
Salvage Therapy | 1 | 2021 | 1277 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 1 | 2018 | 20762 | 0.030 |
Why?
|
Multivariate Analysis | 2 | 2018 | 12096 | 0.030 |
Why?
|
Infant | 3 | 2024 | 36497 | 0.030 |
Why?
|
Checklist | 1 | 2021 | 843 | 0.030 |
Why?
|
Advisory Committees | 1 | 2018 | 797 | 0.030 |
Why?
|
Survival Rate | 2 | 2018 | 12875 | 0.030 |
Why?
|
Child, Preschool | 3 | 2024 | 42623 | 0.030 |
Why?
|
Evidence-Based Medicine | 1 | 2024 | 3708 | 0.030 |
Why?
|
Canada | 1 | 2018 | 2143 | 0.030 |
Why?
|
Inpatients | 1 | 2024 | 2561 | 0.020 |
Why?
|
Europe | 1 | 2018 | 3439 | 0.020 |
Why?
|
Regression Analysis | 1 | 2021 | 6353 | 0.020 |
Why?
|
Critical Illness | 1 | 2023 | 2754 | 0.020 |
Why?
|
Organ Specificity | 1 | 2015 | 1972 | 0.020 |
Why?
|
Palliative Care | 1 | 2024 | 3644 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 1 | 2016 | 36840 | 0.020 |
Why?
|
Registries | 1 | 2024 | 8373 | 0.020 |
Why?
|
Graft Rejection | 1 | 2021 | 4505 | 0.020 |
Why?
|
Infant, Newborn | 2 | 2018 | 26395 | 0.020 |
Why?
|
Patient Care Team | 1 | 2018 | 2526 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2021 | 7863 | 0.020 |
Why?
|
Aged, 80 and over | 2 | 2024 | 59680 | 0.020 |
Why?
|
Reoperation | 1 | 2017 | 4342 | 0.020 |
Why?
|
Mutation | 2 | 2023 | 30243 | 0.020 |
Why?
|
Body Weight | 1 | 2017 | 4630 | 0.020 |
Why?
|
Severity of Illness Index | 1 | 2024 | 15965 | 0.020 |
Why?
|
Proportional Hazards Models | 1 | 2018 | 12561 | 0.010 |
Why?
|
Hospitalization | 1 | 2024 | 10845 | 0.010 |
Why?
|
Cytokines | 1 | 2018 | 7449 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2018 | 14480 | 0.010 |
Why?
|
Stress Disorders, Post-Traumatic | 1 | 2021 | 4636 | 0.010 |
Why?
|
Inflammation | 1 | 2022 | 10865 | 0.010 |
Why?
|
Databases, Factual | 1 | 2018 | 8081 | 0.010 |
Why?
|
Pain | 1 | 2017 | 5096 | 0.010 |
Why?
|
Pandemics | 1 | 2021 | 8753 | 0.010 |
Why?
|
Prevalence | 1 | 2017 | 15880 | 0.010 |
Why?
|
Animals | 2 | 2024 | 169418 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2018 | 18388 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2019 | 15880 | 0.010 |
Why?
|
Cohort Studies | 1 | 2017 | 41797 | 0.010 |
Why?
|
Mice | 1 | 2018 | 82045 | 0.010 |
Why?
|
Neoplasms | 1 | 2020 | 22386 | 0.010 |
Why?
|